Premium
El papel de pfmdr1 en la tolerancia de Plasmodium falciparum a artemeter‐lumefantrina en África
Author(s) -
Sisowath Christin,
Ferreira Pedro E.,
Bustamante Leyla Y.,
Dahlström Sabina,
Mårtensson Andreas,
Björkman Anders,
Krishna Sanjeev,
Gil José P.
Publication year - 2007
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/j.1365-3156.2007.01843.x
Subject(s) - artemether/lumefantrine , plasmodium falciparum , malaria , biology , lumefantrine , drug resistance , virology , medicine , artemisinin , genetics , immunology
Summary Objective Artemether‐lumefantrine (AL), presently the most favoured combination therapy against uncomplicated Plasmodium falciparum malaria in Africa, has recently shown to select for the pfmdr1 86N allele. The objective of this study was to search for the selection of other mutations potentially involved in artemether‐lumefantrine tolerance and/or resistance, i.e. pfmdr1 gene amplification, pfmdr1 Y184F, S1034C, N1042D, D1246Y, pfcrt S163R and PfATP6 S769N. Methods The above mentioned SNPs were analysed by PCR–restriction fragment length polymorphism and pfmdr1 gene amplification by real‐time PCR based protocols in parasites from 200 children treated with AL for uncomplicated P. falciparum malaria in Zanzibar. Results A statistically significant selection of pfmdr1 184F mostly in combination with 86N was seen in reinfections after treatment. No pfmdr1 gene amplification was found. Conclusion The results suggest that different pfmdr1 alleles are involved in the development of tolerance/resistance to lumefantrine.